| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Meghaa S Bhargava, Harmeet Singh Rehan, Dinesh Katari. Olanzapine vs. Risperidone in Schizophrenia: A Cross-sectional Comparison of Quality of Life of Caregivers. Indian journal of physiology and pharmacology. vol 60. issue 2. 2018-07-23. PMID:29809377. |
olanzapine vs. risperidone in schizophrenia: a cross-sectional comparison of quality of life of caregivers. |
2018-07-23 |
2023-08-13 |
human |
| Meghaa S Bhargava, Harmeet Singh Rehan, Dinesh Katari. Olanzapine vs. Risperidone in Schizophrenia: A Cross-sectional Comparison of Quality of Life of Caregivers. Indian journal of physiology and pharmacology. vol 60. issue 2. 2018-07-23. PMID:29809377. |
on the basis of qol of caregivers, olanzapine and risperidone were similarly effective therapeutic agents for schizophrenia. |
2018-07-23 |
2023-08-13 |
human |
| Sajeev Kumar P B, Ravi S Pandey, Jagadisha Thirthalli, Siva Kumar P T, Naveen Kumar . A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. Current neuropharmacology. vol 15. issue 8. 2018-07-16. PMID:28088913. |
a comparative study of short term efficacy of aripiprazole and risperidone in schizophrenia. |
2018-07-16 |
2023-08-13 |
Not clear |
| Hongying Chen, Yong Fan, Lei Zhao, Yong Hao, Xiajun Zhou, Yangtai Guan, Zezhi L. Successful treatment with risperidone increases 5-HT 3A receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. Brain and behavior. vol 7. issue 9. 2018-07-16. PMID:28948091. |
successful treatment with risperidone increases 5-ht 3a receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. |
2018-07-16 |
2023-08-13 |
Not clear |
| Hongying Chen, Yong Fan, Lei Zhao, Yong Hao, Xiajun Zhou, Yangtai Guan, Zezhi L. Successful treatment with risperidone increases 5-HT 3A receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. Brain and behavior. vol 7. issue 9. 2018-07-16. PMID:28948091. |
the relationship between peripheral 5-ht3a receptor mrna level and risperidone efficiency in paranoid schizophrenia patients is still unknown. |
2018-07-16 |
2023-08-13 |
Not clear |
| Mao-Lin Hu, Xiao-Fen Zong, Jun-Jie Zheng, Spiro P Pantazatos, Jeffrey M Miller, Zong-Chang Li, Yan-Hui Liao, Ying He, Jun Zhou, De-En Sang, Hong-Zeng Zhao, Lu-Xian Lv, Jin-Song Tang, J John Mann, Xiao-Gang Che. Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study. Scientific reports. vol 6. 2018-07-10. PMID:27698361. |
short-term effects of risperidone monotherapy on spontaneous brain activity in first-episode treatment-naïve schizophrenia patients: a longitudinal fmri study. |
2018-07-10 |
2023-08-13 |
human |
| Mao-Lin Hu, Xiao-Fen Zong, Jun-Jie Zheng, Spiro P Pantazatos, Jeffrey M Miller, Zong-Chang Li, Yan-Hui Liao, Ying He, Jun Zhou, De-En Sang, Hong-Zeng Zhao, Lu-Xian Lv, Jin-Song Tang, J John Mann, Xiao-Gang Che. Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study. Scientific reports. vol 6. 2018-07-10. PMID:27698361. |
we performed a longitudinal resting-state functional magnetic resonance imaging (fmri) study in 42 treatment-naïve first-episode schizophrenia patients (fesp) at baseline and then after 8-weeks of risperidone monotherapy, and compared the findings to 38 healthy volunteers. |
2018-07-10 |
2023-08-13 |
human |
| Fen Xue, Yun-Chun Chen, Cui-Hong Zhou, Ying Wang, Min Cai, Wen-Jun Yan, Rui Wu, Hua-Ning Wang, Zheng-Wu Pen. Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia. Pharmacology, biochemistry, and behavior. vol 163. 2018-07-10. PMID:29037878. |
risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances notch signaling in a murine model of schizophrenia. |
2018-07-10 |
2023-08-13 |
mouse |
| Fen Xue, Yun-Chun Chen, Cui-Hong Zhou, Ying Wang, Min Cai, Wen-Jun Yan, Rui Wu, Hua-Ning Wang, Zheng-Wu Pen. Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia. Pharmacology, biochemistry, and behavior. vol 163. 2018-07-10. PMID:29037878. |
in the present study, we used a murine model of schizophrenia induced by 5-day intraperitoneal injection with the non-competitive n-methyl-d-aspartate receptor antagonist mk801 (0.3mg/kg/day) to assess cognitive behavioral deficits, changes in notch signaling, and cellular proliferation in the hippocampus of adult male c57bl/6 mice after 2-week administration of risperidone (rip, 0.2mg/kg/day) or vehicle. |
2018-07-10 |
2023-08-13 |
mouse |
| T Zahan, N Akhter, M S I Mullick, Z F Dewa. Metabolic risk factor-profile in patients on treatment with second generation antipsychotics. Bangladesh Medical Research Council bulletin. vol 41. issue 3. 2018-06-28. PMID:29870170. |
the aim of the study was to evaluate the association between olanzapine, risperidone or quetiapine treatment and body mass index, blood pressure, diabetes mellitus and hyperlipidaemia in patients with schizophrenia and bipolar disorder. |
2018-06-28 |
2023-08-13 |
Not clear |
| T Zahan, N Akhter, M S I Mullick, Z F Dewa. Metabolic risk factor-profile in patients on treatment with second generation antipsychotics. Bangladesh Medical Research Council bulletin. vol 41. issue 3. 2018-06-28. PMID:29870170. |
therapeutic use of olanzapine and risperidone in schizophrenia and bipolar disorder for a period of 4th, 8th and 12th weeks was associated with significant increase in body weight and body mass index. |
2018-06-28 |
2023-08-13 |
Not clear |
| Gurjit Kaur, Deepti Gupta, Bir Singh Chavan, Vikas Sinhmar, Rajendra Prasad, Adarsh Tripathi, P D Garg, Rajiv Gupta, Hitesh Khurana, Shiv Gautam, Mushtaq Ahmed Margoob, Jitender Anej. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Asian journal of psychiatry. vol 29. 2018-06-22. PMID:28692863. |
identification of genetic correlates of response to risperidone: findings of a multicentric schizophrenia study from india. |
2018-06-22 |
2023-08-13 |
Not clear |
| Gurjit Kaur, Deepti Gupta, Bir Singh Chavan, Vikas Sinhmar, Rajendra Prasad, Adarsh Tripathi, P D Garg, Rajiv Gupta, Hitesh Khurana, Shiv Gautam, Mushtaq Ahmed Margoob, Jitender Anej. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Asian journal of psychiatry. vol 29. 2018-06-22. PMID:28692863. |
risperidone is most commonly used as an antipsychotic in india for treatment of schizophrenia. |
2018-06-22 |
2023-08-13 |
Not clear |
| Gurjit Kaur, Deepti Gupta, Bir Singh Chavan, Vikas Sinhmar, Rajendra Prasad, Adarsh Tripathi, P D Garg, Rajiv Gupta, Hitesh Khurana, Shiv Gautam, Mushtaq Ahmed Margoob, Jitender Anej. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Asian journal of psychiatry. vol 29. 2018-06-22. PMID:28692863. |
so, we attempted to evaluate the association between dopamine d2 (drd2) receptor, serotonergic (5ht2a) receptor and cyp2d6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from north india. |
2018-06-22 |
2023-08-13 |
Not clear |
| Douglas L Noordsy, Shirley M Glynn, Catherine A Sugar, Christopher D O'Keefe, Stephen R Marde. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. Journal of psychiatric research. vol 95. 2018-06-07. PMID:28942217. |
risperidone versus olanzapine among patients with schizophrenia participating in supported employment: eighteen-month outcomes. |
2018-06-07 |
2023-08-13 |
Not clear |
| Douglas L Noordsy, Shirley M Glynn, Catherine A Sugar, Christopher D O'Keefe, Stephen R Marde. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. Journal of psychiatric research. vol 95. 2018-06-07. PMID:28942217. |
this study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment. |
2018-06-07 |
2023-08-13 |
Not clear |
| Douglas L Noordsy, Shirley M Glynn, Catherine A Sugar, Christopher D O'Keefe, Stephen R Marde. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. Journal of psychiatric research. vol 95. 2018-06-07. PMID:28942217. |
risperidone and olanzapine have similar efficacy and tolerability in patients with schizophrenia who are participating in supported employment. |
2018-06-07 |
2023-08-13 |
Not clear |
| Qijing Bo, Feng Li, Xianbin Li, Zhimin Wang, Fang Dong, Fan He, Anning Li, Xin Ma, Chuanyue Wan. Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study. Psychiatry research. vol 258. 2018-05-31. PMID:28865716. |
symptomatic remission in schizophrenia: results from a risperidone maintenance treatment study. |
2018-05-31 |
2023-08-13 |
Not clear |
| Qijing Bo, Feng Li, Xianbin Li, Zhimin Wang, Fang Dong, Fan He, Anning Li, Xin Ma, Chuanyue Wan. Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study. Psychiatry research. vol 258. 2018-05-31. PMID:28865716. |
this study aimed to investigate remission following the treatment of schizophrenia patients with risperidone. |
2018-05-31 |
2023-08-13 |
Not clear |
| Qijing Bo, Feng Li, Xianbin Li, Zhimin Wang, Fang Dong, Fan He, Anning Li, Xin Ma, Chuanyue Wan. Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study. Psychiatry research. vol 258. 2018-05-31. PMID:28865716. |
clinically stabilized patients with schizophrenia (n = 374) were randomly assigned to 4-week, 26-week, or no-dose-reduction groups, in which the baseline risperidone dose was continued for 4, 26, or all weeks during 1-year period. |
2018-05-31 |
2023-08-13 |
Not clear |